Mar 21 |
LAVA Therapeutics GAAP EPS of -$0.24 beats by $0.18
|
Mar 21 |
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
|
Mar 20 |
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
|
Mar 5 |
Lava gets $7M from Pfizer as trial for cancer drug advances
|
Mar 5 |
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
|
Jan 25 |
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
|
Jan 25 |
LAVA stock rises on clinical trial collaboration with Merck
|
Jan 25 |
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
|
Nov 16 |
LAVA Therapeutics GAAP EPS of -$0.34 beats by $0.14
|
Nov 16 |
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
|